Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations. This is an ASCO Meeting Abstract from the 2018 ASCO Annual ...
SEATTLE--(BUSINESS WIRE)--#Virtualcare--Tasso, Inc., a leader in clinical-grade blood collection solutions, today announced the launch of Tasso PopPK Solutions, an integrated patient-centric offering ...
Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results